Kratom-induced Psychosis

Case report and literature investigation


  • Sebastien S Prat McMaster University & St. Joseph's Healthcare Hamilton
  • Syed Ali Rizvi McMaster University, Michael DeGroote’s School of Medicine, Faculty of Health Sciences
  • Gary A Chaimowitz McMaster University, Department of Psychiatry and Behavioural Neurosciences



Psychosis, Schizophrenia, Kratom, Mitragyna speciasa, drug-induced, legal highs


Substance Use Disorder is a major concern for public health. Legal substances are often misused to get “high”. Beside the risk of developing subsequent mental health and physical conditions, one of major risk is related to behavioural changes leading to criminal behaviour. There is need for regulation on some of these substances to ensure public as well as individual safety. This article is a case report describing Mitragyna speciosa (Kratom) induced psychosis in a patient suffering from Schizophrenia. We hope this article can bring attention to regulating bodies about the risks associated with readily available “legal” drugs like Kratom. 


Hillebrand J, Olszewski D, Sedefov R. Legal highs on the Internet. Subst Use Misuse. 2010;45(3):330‑40.

Williams RJ, Nowatzki N. Validity of adoles-cent self-report of substance use. Subst Use Misuse. 2005;40(3):299‑311.

Mooney L. Drugs of abuse: what you & clinicians need to know. 2015. (accessed on September 9, 2019).

Kikura-Hanajiri R, Kawamura M, Maruyama T, Kitajima M, Takayama H, Goda Y. Simultaneous analysis of mitragynine, 7-hydroxymitragynine, and other alkaloids in the psychotropic plant “kratom” (Mitragyna speciosa) by LC-ESI-MS. Forensic Toxicol. 2009;27(2):67‑74.

Hassan Z, Muzaimi M, Navaratnam V, Yusoff NHM, Suhaimi FW, Vadivelu R, et al. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev. 2013;37(2):138‑51.

Kratom Legend. Kratom Strains & Their Inside Nature. (accessed 09 September 2019). Kratom Strains and localities. (accessed on September 9, 2019).

Tavakoli HR, Buchholz AC, Kabir IK, Deb A, Gayk JN. Kratom: a new product in an expanding substance abuse market. Fed Pract. 2016;33(11):32‑6.

Winstock A, Wilkins C. “Legal highs” the challenge of new psychoactive substances. Ser Legis Reform Drug Policies. 2011. (accessed on September 9, 2019).

Neerman MF, Frost RE, Deking J. A drug fatality involving kratom. J Forensic Sci. 2013;58:S278‑9.

Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid with-drawal using kratom (Mitragynia speciosa korth). Addict Abingdon Engl. 2008;103(6):1048‑50.

Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM. Seizure and coma following kratom (Mi-tragynina speciosa Korth) exposure. J Med Toxicol. 2010;6(4):424‑6.

Vijeepallam K, Pandy V, Kunasegaran T, Murugan DD, Naidu M. Mitragyna speciosa leaf extract exhibits antipsychotic-like effect with the potential to alleviate positive and negative symptoms of psychosis in mice. Front Pharmacol. 2016. (accessed on September 9, 2019).

Anwar M, Law R, Schier J. Notes from the field: Kratom (Mitragyna speciosa) exposures reported to poison centers — United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65(29):748‑9.

Kittirattanapaiboon P, Suttajit S, Junsiri-mongkol B, Likhitsathian S, Srisurapanont M. Suicide risk among Thai illicit drug users with and without mental/alcohol use disorders. Neuropsychiatr Dis Treat. 2014;453.

Suwanlert S. A study of kratom eaters in Thailand. Bull Narc. 1975;27(3):21‑7.

Chang-Chien GC, Odonkor CA, Amorapanth P. Is Kratom the new “legal high” on the block?: the case of an emerging opioid receptor agonist with substance abuse potential. Pain Physician. 2017;20(1):E195‑8.

Burillo-Putze G, López Briz E, Climent Díaz B, Munné Mas P, Nogue Xarau S, Pinillos MA, et al. [Emergent drugs (III): hallucinogenic plants and mushrooms]. An Sist Sanit Navar. 2013;36(3):505‑18.

Junsirimongkol B. Kratom abuse in Southern Thailand. 2008. (accessed on September 9, 2019).

Shreeram SS, McDonald T, Dennison S. Psychosis after ultrarapid opiate detoxification. Am J Psychiatry. 2001;158(6):970‑970.

Singh D, Müller CP, Vicknasingam BK. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend. 2014;139:132‑7.

European Monitoring Center for Drug and Drug Addictions. Kratom (Mitragyna speciosa) drug profile. (accessed on September 9, 2019).

Swogger MT, Hart E, Erowid F, Erowid E, Tra-bold N, Yee K, et al. Experiences of kratom users: a qualitative analysis. J Psychoactive Drugs. 2015;47(5):360‑7.

Davies S, Wood DM, Smith G, Button J, Ram-sey J, Archer R, et al. Purchasing « legal highs » on the Internet--is there consistency in what you get? QJM. 2010;103(7):489‑93.

Babu KM, McCurdy CR, Boyer EW. Opioid receptors and legal highs: Salvia divinorum and Kratom. Clin Toxicol Phila Pa. 2008;46(2):146‑52.

U.S. Drug Enforcement Administration, Office of Diversion Control. KRATOM (Mitragyna speciosa korth). 2013. (accessed on September 9, 2019).

Forrester MB. Kratom exposures reported to Texas poison centers. J Addict Dis. 2013;32(4):396‑400.

Schmidt MM, Sharma A, Schifano F, Feinmann C. “Legal highs” on the net—evaluation of UK-based websites, products and product information. Forensic Sci Int. 2011;206(1‑3):92‑7.

Sheleg SV, Collins GB. A Coincidence of Addiction to “Kratom” and severe primary hypothyroidism. J Addict Med. 2011;5(4):300‑1.

McWhirter L, Morris S. A case report of inpatient detoxification after kratom (Mitragyna speciosa) dependence. Eur Addict Res. 2010;16(4):229‑31.

Prozialeck WC, Jivan JK, Andurkar SV. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012;112(12):792‑9.

Trakulsrichai S, Tongpo A, Sriapha C, Wongvisawakorn S, Rittilert P, Kaojarern S, et al. Kratom abuse in Ramathibodi poison center, Thailand: a five-year experience. J Psychoactive Drugs. 2013;45(5):404‑8

Voelker R. Kratom products seized. JAMA. 2016;316(11):1142.

Yusoff NHM, Suhaimi FW, Vadivelu RK, Has-san Z, Rümler A, Rotter A, et al. Abuse potential and adverse cognitive effects of mitragynine (kratom): Mitragynine addiction. Addict Biol. 2016;21(1):98‑110.




How to Cite

Prat, S. S., Rizvi, S. A., & Chaimowitz, G. A. (2020). Kratom-induced Psychosis: Case report and literature investigation. International Journal of Risk and Recovery, 3(1), 29–34.



Case Reports

Most read articles by the same author(s)